467 related articles for article (PubMed ID: 34108185)
1. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
[TBL] [Abstract][Full Text] [Related]
2. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
4. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
5. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies in cancer immunotherapy.
Chen S; Li J; Li Q; Wang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
[TBL] [Abstract][Full Text] [Related]
8. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies for cancer immunotherapy: Current perspectives.
Müller D; Kontermann RE
BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
[TBL] [Abstract][Full Text] [Related]
10. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
12. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
13. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Wu Z; Cheung NV
Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
15. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
16. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
17. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
18. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.
Ellerman D
Methods; 2019 Feb; 154():102-117. PubMed ID: 30395966
[TBL] [Abstract][Full Text] [Related]
19. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]